ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
December 20 2018 - 1:48AM
Business Wire
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet medical needs in central
nervous system disorders, today announced that it will present at
the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
on Wednesday, January 9, 2019, at 11:00 a.m. Pacific Standard Time,
followed by a question and answer breakout session at 11:30
a.m.
A live webcast of ACADIA’s presentation and breakout session
will be accessible on the company’s website, www.acadia-pharm.com,
under the investors section and an archived recording will be
available on the website through February 6, 2019.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA has
developed and is commercializing the first and only medicine
approved for the treatment of hallucinations and delusions
associated with Parkinson’s disease psychosis. In addition, ACADIA
has ongoing clinical development efforts in additional areas with
significant unmet need, including dementia-related psychosis,
schizophrenia inadequate response, schizophrenia-negative symptoms,
major depressive disorder and Rett syndrome. This press release and
further information about ACADIA can be found at:
www.acadia-pharm.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181220005196/en/
Investor Contact: ACADIA Pharmaceuticals Inc. Elena Ridloff, CFA
(858) 558-2871 ir@acadia-pharm.com
Media Contact: ACADIA Pharmaceuticals Inc. Maurissa Messier
(858) 768-6068 media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024